Football's Writer Program can give you the edge you need to get ahead. Apply Now ...

2024 at 8:20 AM ET and participate in one-on-one investor me New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which ...

The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and ...

The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...

该研究显示出显著的纤维化改善效果，使得Leerink模型中pegozafermin在F4 NASH中的成功概率提高到60%。 此外，89bio最近宣布与Goldman Sachs & Co. LLC、Leerink Partners LLC和BofA Securities, Inc.达成承销协议。该协议涉及发行超过2,100万股股票和预付认股权证，预计将产生约$234.6 ...